Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AEGEAN perioperative durvalumab in resectable stage II-III non-small cell lung cancer
NL-OMON52504Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Sep 2020
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Durvalumab + chemotherapy followed by durvalumab with Placebo + chemotherapy followed by placebo (2 arms). Primary endpoints: Event-free survival and Major pathologic response. Started Sep 2020; status: active, not recruiting.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON52504.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52504.